The European Commission has approved Novo Nordisk's oral semaglutide 25 mg tablet (Wegovy pill) for weight management, marking the first oral GLP-1 receptor agonist available in the EU. The approval is for adults with obesity or overweight with comorbidities. Additionally, the EC approved a 7.2 mg single-dose pen injection. Novo Nordisk plans to launch the tablet in the EU in the second half of 2026.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.